Across TCGA pan-cancer cohorts, FAM3B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM3B data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher FAM3B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM3B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, BLCA, and CESC are the cancer types where FAM3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.115	0.669	<.001	18	view →
BLCA	OS	Median	All	0.228	0.720	.010	12	view →
CESC	DFS	Median	All	0.260	0.740	.042	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.681	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FAM3B tumor-vs-normal RNA expression · all FAM3B data types